Moors & Cabot Inc. decreased its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 8.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 18,760 shares of the medical research company's stock after selling 1,689 shares during the period. Moors & Cabot Inc.'s holdings in Amgen were worth $4,890,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently made changes to their positions in AMGN. Charles Schwab Investment Management Inc. boosted its stake in Amgen by 25.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 13,205,604 shares of the medical research company's stock valued at $3,441,909,000 after buying an additional 2,672,975 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in Amgen during the fourth quarter valued at approximately $401,913,000. Van ECK Associates Corp raised its position in Amgen by 263.8% during the fourth quarter. Van ECK Associates Corp now owns 1,038,593 shares of the medical research company's stock valued at $270,699,000 after purchasing an additional 753,147 shares during the period. Nordea Investment Management AB raised its position in Amgen by 40.7% during the fourth quarter. Nordea Investment Management AB now owns 2,338,665 shares of the medical research company's stock valued at $609,526,000 after purchasing an additional 676,598 shares during the period. Finally, Janus Henderson Group PLC raised its position in Amgen by 11.7% during the third quarter. Janus Henderson Group PLC now owns 5,143,330 shares of the medical research company's stock valued at $1,657,183,000 after purchasing an additional 538,545 shares during the period. Institutional investors own 76.50% of the company's stock.
Amgen Stock Performance
Shares of AMGN stock opened at $318.89 on Wednesday. The firm has a market capitalization of $171.31 billion, a price-to-earnings ratio of 42.24, a price-to-earnings-growth ratio of 2.63 and a beta of 0.53. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. The business has a fifty day moving average of $288.66 and a 200 day moving average of $299.43. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85.
Amgen (NASDAQ:AMGN - Get Free Report) last issued its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. As a group, research analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.
Amgen Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be paid a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 2.99%. Amgen's payout ratio is currently 126.09%.
Insider Buying and Selling at Amgen
In other Amgen news, SVP Nancy A. Grygiel sold 1,589 shares of Amgen stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the transaction, the senior vice president now owns 7,210 shares in the company, valued at approximately $2,195,228.70. This trade represents a 18.06 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP David M. Reese sold 25,225 shares of Amgen stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $304.44, for a total value of $7,679,499.00. Following the completion of the transaction, the executive vice president now owns 36,922 shares of the company's stock, valued at approximately $11,240,533.68. This represents a 40.59 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 69,341 shares of company stock worth $20,644,335. Insiders own 0.69% of the company's stock.
Analyst Ratings Changes
Several equities research analysts have recently weighed in on AMGN shares. Redburn Partners reduced their price target on Amgen from $200.00 to $195.00 in a report on Wednesday, November 27th. Piper Sandler increased their price target on Amgen from $310.00 to $329.00 and gave the stock an "overweight" rating in a report on Monday, February 10th. Deutsche Bank Aktiengesellschaft reduced their price target on Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. William Blair reiterated an "outperform" rating on shares of Amgen in a report on Tuesday, November 12th. Finally, Piper Sandler Companies reiterated an "overweight" rating and issued a $310.00 price target on shares of Amgen in a report on Thursday, January 2nd. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Amgen currently has a consensus rating of "Hold" and an average price target of $314.04.
Check Out Our Latest Research Report on Amgen
Amgen Company Profile
(
Free Report)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
